Table 4.
Clinical, laboratory and vascular features in SLE patients (n=22) over time
| Feature | Baseline | Follow-up | p Value |
|---|---|---|---|
| BP systolic (mm Hg) | 131 (104, 144) | 134 (118, 154) | 0.24 |
| BP diastolic (mm Hg) | 77 (66, 85) | 75 (67, 85) | 0.88 |
| BMI (kg/m2) | 26.6 (22.5, 28.5) | 26.7 (24.2, 32.7) | 0.34 |
| WC (cm) | 84.9 (76, 94) | 86 (78.5, 94.7) | 0.55 |
| Total cholesterol (mmol/l) | 5.22 (4.71, 6.32) | 5.19 (4.60, 6.37) | 0.81 |
| HDL-cholesterol (mmol/l) | 1.33 (1.24, 1.59) | 1.45 (1.33, 1.63) | 0.32 |
| LDL-cholesterol (mmol/l) | 2.86 (1.90, 3.60) | 2.66 (2.33, 3.47) | 0.88 |
| Triglycerides (mmol/l) | 1.45 (0.9, 1.9) | 1.1 (0.9, 1.62) | 0.34 |
| Glucose (mmol/l) | 4.4 (4.1, 5.1) | 4.7 (4.1, 4.9) | 0.81 |
| MetS | 10 (45.5) | 9 (40.9) | 0.86 |
| hsCRP (mg/l) | 2.47 (0.96, 5.11) | 4.57 (1.36, 7.37) | 0.15 |
| Adiponectin (mg/l) | 3.60 (2.76, 5.90) | 3.80 (2.96, 4.84) | 0.58 |
| Fasting insulin (mU/l) | 16.1(12.4, 22.9) | 17.2 (11.8, 26.4) | 0.77 |
| HOMA2-IR | 2.4 (1.8, 4.0) | 2.6 (1.8, 3.7) | 0.80 |
| SLEDAI-2K | 6 (4, 14) | 4 (2, 6) | <0.001 |
| Global BILAG-2004 score | 17 (12, 22) | 3 (2, 9) | <0.001 |
| Elevated anti-dsDNA | 9 (40.9) | 5 (22.7) | 0.23 |
| Low complement | 7 (31.8) | 4 (18.2) | 0.44 |
| Baseline BA diameter (mm) | 3.53 (3.12, 3.85) | 3.38 (3.21, 3.85) | 0.81 |
| % FMD (at 60 s) | 0.64 (−2.31, 4.47) | 3.52 (0.98, 5.50) | 0.10 |
| % FMD (maximum) | 1.40 (0.54, 4.47) | 4.56 (1.71, 5.87) | 0.19 |
| FMD <5% (at 60 s) | 86.7% | 66.7% | 0.20 |
| EMPs (n/ml) | 162265 (59906, 278775) | 55655 (29475, 188659) | 0.02 |
| VEGF (pg/ml) | 99 (53, 155) | 71 (27, 141) | 0.14 |
| VCAM-1 (ng/ml) | 488 (375, 587) | 458 (297, 488) | 0.17 |
| sEPCR (ng/ml) | 49.3 (43.6, 67.3) | 47.0 (36.7, 72.8) | 0.79 |
Unless otherwise indicated, values are median (IQR) or n (%).
BA, brachial artery; BILAG, British Isles Lupus Assessment Group Disease Activity Index; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; EMP, endothelial microparticle; FMD, flow-mediated dilatation; HDL, high-density lipoprotein; HOMA2-IR, homoeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MetS, metabolic syndrome; sEPCR, soluble endothelial protein c receptor; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; WC, waist circumference.